The stock of MoonLake Immunotherapeutics (MLTX) has seen a -4.33% decrease in the past week, with a 5.50% gain in the past month, and a 26.42% flourish in the past quarter. The volatility ratio for the week is 4.57%, and the volatility levels for the past 30 days are at 4.60% for MLTX. The simple moving average for the past 20 days is 2.98% for MLTX’s stock, with a 4.63% simple moving average for the past 200 days.
Is It Worth Investing in MoonLake Immunotherapeutics (NASDAQ: MLTX) Right Now?
Moreover, the 36-month beta value for MLTX is 1.26. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 9 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MLTX is 52.49M and currently, short sellers hold a 14.81% of that float. On September 26, 2024, MLTX’s average trading volume was 322.76K shares.
MLTX) stock’s latest price update
MoonLake Immunotherapeutics (NASDAQ: MLTX)’s stock price has gone decline by -6.36 in comparison to its previous close of 54.26, however, the company has experienced a -4.33% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-09-09 that MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from 2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CET The event will provide business updates from MoonLake’s CEO Jorge Santos da Silva, CSO Kristian Reich and CFO Matthias Bodenstedt and include details on the Phase 3 programs for our investigational Nanobody® sonelokimab (SLK) in hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). In addition, MoonLake will provide pipeline updates and details on additional catalysts for the 2024-2026 period, including for trials in new indications such as the Phase 2 trials of SLK in palmo-plantar pustulosis (PPP).
Analysts’ Opinion of MLTX
Oppenheimer, on the other hand, stated in their research note that they expect to see MLTX reach a price target of $104. The rating they have provided for MLTX stocks is “Outperform” according to the report published on June 25th, 2024.
Goldman gave a rating of “Neutral” to MLTX, setting the target price at $62 in the report published on April 02nd of the current year.
MLTX Trading at 7.85% from the 50-Day Moving Average
After a stumble in the market that brought MLTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.81% of loss for the given period.
Volatility was left at 4.60%, however, over the last 30 days, the volatility rate increased by 4.57%, as shares surge +8.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.24% upper at present.
During the last 5 trading sessions, MLTX fell by -4.33%, which changed the moving average for the period of 200-days by -8.04% in comparison to the 20-day moving average, which settled at $49.53. In addition, MoonLake Immunotherapeutics saw -15.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MLTX starting from Santos da Silva Jorge, who sale 62,810 shares at the price of $55.00 back on Feb 27 ’24. After this action, Santos da Silva Jorge now owns 3,043,619 shares of MoonLake Immunotherapeutics, valued at $3,454,550 using the latest closing price.
Santos da Silva Jorge, the Chief Executive Officer of MoonLake Immunotherapeutics, sale 56,065 shares at $55.00 during a trade that took place back on Feb 28 ’24, which means that Santos da Silva Jorge is holding 2,987,554 shares at $3,083,575 based on the most recent closing price.
Stock Fundamentals for MLTX
Current profitability levels for the company are sitting at:
- -3972.25 for the present operating margin
- -1.91 for the gross margin
The net margin for MoonLake Immunotherapeutics stands at -2776.56. The total capital return value is set at -0.15. Equity return is now at value -10.85, with -10.42 for asset returns.
Based on MoonLake Immunotherapeutics (MLTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -19.27. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -19.91.
Currently, EBITDA for the company is -54.11 million with net debt to EBITDA at 4.33. When we switch over and look at the enterprise to sales, we see a ratio of 144691.59. The receivables turnover for the company is 0.01for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 43.71.
Conclusion
To wrap up, the performance of MoonLake Immunotherapeutics (MLTX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
